.Attribute Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ sophisticated breast cancer cells and active or dependable mind metastases presented constant intracranial activity and also systemic efficiency of T-DXd.